Cosmos Holdings to launch Sky Premium Life nutritional supplements on Amazon UK Other OTC: COSM
CHICAGO, April 27, 2021 (GLOBE NEWSWIRE) – Cosmos Holdings, Inc. (“The Company”) (OTCQX: COSM), a vertically integrated international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medicines and an extensive distribution network established in the European Union, announced today that the Company’s subsidiary , Decahedron Ltd, a UK based pharmaceutical wholesaler, distributor and distributor, has launched the launch of 65 Sky Premium Life products on Amazon UK.
PAGB, the consumer health association that represents manufacturers of branded over-the-counter medicines, self-care medical devices and dietary supplements in the UK, worked with Decahedron on the regulatory process for bringing the products to market. Sky Premium Life in the UK. Cosmos expects ten Sky Premium Life SKUs to launch next month and target the 65 SKUs listed on Amazon UK by the end of the year.
According to a Mintel study, the UK vitamins and minerals market grew 14.3% in 2020 compared to the previous year, from Â£ 434million to Â£ 494million, and showing major adoption of these products by UK consumers. UK sales of all consumer health products peaked in March 2020, up 125.8% year-on-year. With Covid-19 lockdowns and restrictions on store capacity, consumers have increasingly turned to online shopping and there are signs that this trend is likely to continue.
Additionally, according to Mintel research, 24% of vitamin, mineral, and dietary supplement (VMS) users have taken more vitamins and supplements since the COVID-19 outbreak. Immune health has become a priority since the start of the pandemic, with 36% of VMS users taking them to boost their immune systems and around one in seven using them to improve their mood (15%) and combat stress (13%). ).
Greg Siokas, CEO of Cosmos Holdings, said: âThe launch of our Sky Premium Life products on Amazon UK offers Cosmos an opportunity for exponential growth, driven by a much greater reliance on both VMS consumption and online shopping. This allows us to profitably reach tens of millions of customers in the UK and the rest of the world which in turn should help grow the brand and provide consumers and retailers with a showcase virtual for all our products. “
âThis is an important step for Cosmos and a major step forward in the deployment of our e-commerce and online distribution strategy. The Amazon UK initiative complements our global sales strategy. We have successfully built a strong distribution network, which now includes 160 wholesale pharmaceutical distributors in 16 countries, with access to over 50,000 physical pharmacies, âhe added.
âWe will continue to add distributors around the world and plan to enter a number of new European and global markets this year. I am confident that our e-commerce strategy will yield a high return on investment given the favorable and growing brand awareness and growing global demand for VMS, âconcluded Mr. Siokas.
About Cosmos Holdings, Inc.
Cosmos Holdings Inc. is an international pharmaceutical company, with an exclusive line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medicines and medical devices and an extensive distribution network established in the EU. The Company identifies, acquires, develops and markets products that improve the lives and outcomes of patients. It has an extensive network of clients in Germany, UK, UAE, Denmark, Italy, France, Singapore, Ireland, Sweden, Poland, Netherlands and Greece . Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece, Athens, Greece and Harlow, UK. More information is available at www.cosmosholdingsinc.com and www.skypremiumlife.com.
With the exception of historical information contained in this press release, the matters described in this press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934., as amended. Statements preceded, followed by or which include the words “believes”, “expects”, “anticipates”, “intends”, “projects”, “estimates”, “plans” and similar expressions or future verbs or Conditions such as like âwillâ, âshouldâ, âwouldâ, âcouldâ and âcouldâ, are generally forward-looking in nature and not historical facts, although all forward-looking statements do not include the foregoing. These statements involve unknown risks and uncertainties which may individually or materially impact the matters discussed herein for various reasons beyond the control of the Company, including, but not limited to the ability of the Company. to mobilize sufficient funding to implement its business plans, the impact of the COVID-19 pandemic on the business, operations and economy of society in general, and the ability of the company to develop and market with success its exclusive products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set out in the Company’s filings with the SEC, which are available on the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Crescendo Communications, LLC
E-mail: [email protected]